Business Description
CellaVision AB
ISIN : SE0000683484
Share Class Description:
STU:C26: Bearer ShsCompare
Compare
Traded in other countries / regions
CEVI.SwedenC26.Germany0MR5.UKCLVSF.USA IPO Date
2017-05-17Description
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers/software.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.89 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | 0.19 | |||||
| Interest Coverage | 114.13 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 17.28 | |||||
| Beneish M-Score | -2.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.8 | |||||
| 3-Year EBITDA Growth Rate | 12.2 | |||||
| 3-Year EPS without NRI Growth Rate | 13.3 | |||||
| 3-Year FCF Growth Rate | 43.2 | |||||
| 3-Year Book Growth Rate | 18.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 23.33 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.86 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.49 | |||||
| 9-Day RSI | 46.64 | |||||
| 14-Day RSI | 43.25 | |||||
| 6-1 Month Momentum % | -6.67 | |||||
| 12-1 Month Momentum % | 39.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.04 | |||||
| Quick Ratio | 2.15 | |||||
| Cash Ratio | 1.06 | |||||
| Days Inventory | 186.4 | |||||
| Days Sales Outstanding | 48.25 | |||||
| Days Payable | 56.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.99 | |||||
| Dividend Payout Ratio | 0.36 | |||||
| Forward Dividend Yield % | 0.99 | |||||
| 5-Year Yield-on-Cost % | 0.99 | |||||
| Shareholder Yield % | 1.67 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.99 | |||||
| Operating Margin % | 25.62 | |||||
| Net Margin % | 20.38 | |||||
| FCF Margin % | 20.69 | |||||
| ROE % | 20.52 | |||||
| ROA % | 15.85 | |||||
| ROIC % | 19.17 | |||||
| ROC (Joel Greenblatt) % | 74.74 | |||||
| ROCE % | 23.1 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 37.36 | |||||
| Forward PE Ratio | 26.33 | |||||
| PE Ratio without NRI | 37.36 | |||||
| Shiller PE Ratio | 50.57 | |||||
| Price-to-Owner-Earnings | 53.86 | |||||
| PEG Ratio | 3.31 | |||||
| PS Ratio | 7.6 | |||||
| PB Ratio | 7.3 | |||||
| Price-to-Tangible-Book | 18.17 | |||||
| Price-to-Free-Cash-Flow | 36.78 | |||||
| Price-to-Operating-Cash-Flow | 24.49 | |||||
| EV-to-EBIT | 26.93 | |||||
| EV-to-Forward-EBIT | 21.51 | |||||
| EV-to-EBITDA | 26.93 | |||||
| EV-to-Forward-EBITDA | 18.18 | |||||
| EV-to-Revenue | 6.95 | |||||
| EV-to-Forward-Revenue | 5.99 | |||||
| EV-to-FCF | 36.1 | |||||
| Price-to-Projected-FCF | 3.15 | |||||
| Price-to-DCF (Earnings Based) | 0.92 | |||||
| Price-to-DCF (FCF Based) | 1.36 | |||||
| Price-to-Median-PS-Value | 0.64 | |||||
| Price-to-Peter-Lynch-Fair-Value | 4.95 | |||||
| Price-to-Graham-Number | 5.45 | |||||
| Price-to-Net-Current-Asset-Value | 30.86 | |||||
| Earnings Yield (Greenblatt) % | 3.69 | |||||
| FCF Yield % | 2.92 | |||||
| Forward Rate of Return (Yacktman) % | 8.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CellaVision AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 65.338 | ||
| EPS (TTM) (€) | 0.559 | ||
| Beta | 1.57 | ||
| Volatility % | 58.18 | ||
| 14-Day RSI | 43.25 | ||
| 14-Day ATR (€) | 0.650551 | ||
| 20-Day SMA (€) | 19.8305 | ||
| 12-1 Month Momentum % | 39.1 | ||
| 52-Week Range (€) | 14.62 - 25.65 | ||
| Shares Outstanding (Mil) | 23.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CellaVision AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CellaVision AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
CellaVision AB Frequently Asked Questions
What is CellaVision AB(STU:C26)'s stock price today?
The current price of STU:C26 is €19.44. The 52 week high of STU:C26 is €25.65 and 52 week low is €14.62.
When is next earnings date of CellaVision AB(STU:C26)?
The next earnings date of CellaVision AB(STU:C26) is 2025-02-06.
Does CellaVision AB(STU:C26) pay dividends? If so, how much?
The Dividend Yield %  of CellaVision AB(STU:C26) is 0.99% (As of Today), Highest Dividend Payout Ratio of CellaVision AB(STU:C26) was 0.6. The lowest was 0.14. And the median was 0.4. The  Forward Dividend Yield % of CellaVision AB(STU:C26) is 0.99%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers